Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN
Untitled Document
 

_____ Brought to you by Bruker _____

Oligonucleotide Analysis Simplified!
MALDI and ESI Solutions

REGISTER NOW

 

  April 24, 2019

  8:00 a.m. PDT, 11:00 a.m. EDT, 16:00 BST, 17:00 CEST

 

Overview

 

There has been noteworthy progress in the oligonucleotide therapeutics field over the past 30 years, beginning with antisense oligonucleotides (ASOs) and aptamers and followed about 15 years ago by siRNAs. Recent innovations in gene editing field is driving the need for oligonucleotides characterization.

MALDI and ESI Mass Spectrometry have prominent roles to play in the life cycle of oligonucleotide drugs from discovery to QC for determination of the molecular weights of natural and synthetic oligonucleotides and in sequencing of DNA and RNA species. Both techniques also have their specific strengths and drawbacks. MALDI-TOF is relatively easy to operate, offers high sensitivity for oligonucleotides, and is well suited to a high-throughput environment. MALDI‐TOF is also reasonably tolerant to the presence of salts, buffers, and other additives. Alternatively, ESI technology maintains high mass accuracy, resolution, and sensitivity over a range of lengths (20–120 bases), but has a reduced throughput and requires more attention to sample cleanliness.

Bruker offers a complete solution for oligonucleotide screening and QC applications with a broad portfolio of innovative and best-in-class MALDI-TOF and UHR ESI-TOF instruments and an integrated software solution for both techniques.

BioPharma Compass 3.1 enables the routine analysis of biopharmaceuticals offering dedicated LC MS workflows including automated measurements and report generation. Both high resolution ESI-QTOF and MALDI-TOF data can be employed for these analyses. Similarity scores and mass accuracy attributes are the basis for an automatic pass/fail assessment. Reports utilize color coding of results and charts for rapid reviewing. Butterfly plots enable visual dataset comparisons.

Brought to you by:

 

Key Learning Objectives

  • Role of Oligonucleotides in drug discovery
  • Oligonucleotide analysis by MALDI and ESI UHR QTOF instruments
  • Biopharma Compass – an integrated software solution for both MALDI and ESI data

Who Should Attend

  • Scientists interested in screening and QC of oligonucleotide drugs
  • Scientists interested in MALDI and ESI analysis of oligonucleotides
 

Speaker

Anjali Alving,
Senior Applications Scientist,
Bruker Scientific
 

Moderator

Jeff Huber,
Contributing Editor,
C&EN Media Group
 

REGISTER NOW